Books on the topic 'Drug patents'

Environment, United States Congress House Committee on Energy and Commerce Subcommittee on Health and the. Drug issues. U.S. G.P.O., 1988.

Patently innovative: How pharmaceutical firms use emerging patent law to extend monopolies on blockbuster drugs. Biohealthcare, 2012.

Shachar, Josh Yehoshua. Frontiers in drug delivery: Pharmaco-kinesis collected patents. Pharmaco-Kinesis Corporation, 2010.

Significant pharmaceuticals reported in recent US patents. Elsevier, 2007.

Ahn, Hyewon. Second generation patents in pharmaceutical innovation. Nomos, 2014.

Voet, Martin A. The generic challenge: Understanding patents, FDA & pharmaceutical life-cycle management. 2nd ed. BrownWalker Press, 2008.

Intellectual property, pharmaceuticals and public health: Access to drugs in developing countries. Edward Elgar, 2011.

United States. Congress. Senate. Committee on Labor and Human Resources. Animal Drug Amendments and Patent Term Restoration Act of 1986: Report together with minority views (to accompany S. 2407). U.S. G.P.O., 1986.

United States. Congress. Senate. Committee on Labor and Human Resources. Animal Drug Amendments and Patent Term Restoration Act of 1986: Report together with minority views (to accompany S. 2407). U.S. G.P.O., 1986.

Resources, United States Congress Senate Committee on Labor and Human. Animal Drug Amendments and Patent Term Restoration Act of 1986: Report together with minority views (to accompany S. 2407). U.S. G.P.O., 1986.

United States. Federal Trade Commission. Generic drug entry prior to patent expiration: An FTC study. W.S. Hein, 2003.

Commission, United States Federal Trade. Generic drug entry prior to patent expiration: An FTC study. U.S. FTC, 2002.

American Bar Association. Section of Intellectual Property Law, ed. Pre-ANDA litigation: Strategies and tactics for developing a drug product and patent portfolio. ABA Section of Intellectual Property Law, 2014.

Mansur, Yasmine Santos. Direito à propriedade intelectual versus saúde pública: O acesso a medicamentos. Editora Appris, 2011.

United States. Congress. Senate. Committee on Labor and Human Resources. Animal Drug Amendments and Patent Term Restoration Act of 1986: Hearing before the Committee on Labor and Human Resources, United States Senate, Ninety-ninth Congress, second session, on S. 2407 ... July 18, 1986. U.S. G.P.O., 1986.

Resources, United States Congress Senate Committee on Labor and Human. Animal Drug Amendments and Patent Term Restoration Act of 1986: Hearing before the Committee on Labor and Human Resources, United States Senate, Ninety-ninth Congress, second session, on S. 2407 ... July 18, 1986. U.S. G.P.O., 1986.

Resources, United States Congress Senate Committee on Labor and Human. Animal Drug Amendments and Patent Term Restoration Act of 1986: Hearing before the Committee on Labor and Human Resources, United States Senate, Ninety-ninth Congress, second session, on S. 2407 ... July 18, 1986. U.S. G.P.O., 1986.

Yufen, Huang, ed. Nai mi yao wu chuan shu ji shu zhuan li di tu ji fen xi: Patent analysis of drug delivery nanotechnology. Guo jia shi yan yan jiu yuan ke ji zheng ce yan jiu yu zi xun zhong xin, 2005.

Closing the gaps in Hatch-Waxman: Assuring greater access to affordable pharmaceuticals : hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Seventh Congress, second session on examining certain provisions of the 1984 Drug Price Competition and Patent Term Restoration Act, known as the Hatch-Waxman Act, assuring greater access to affordable pharmaceuticals, May 8, 2002. U.S. G.P.O., 2002.

Ahn, Hyewon. Patentability of chemical selection inventions: The Olanzapine and Escitalopram decisions. Nomos, 2011.

Lanjouw, Jean Olson. Patents, price controls, and access to new drugs: How policy affects global market entry. National Bureau of Economic Research, 2005.

United States. Congress. Senate. A bill to provide equitable relief for the generic drug industry, and for other purposes. [United States Government Printing Office], 1995.

Biologics and biosimilars: Balancing incentives for innovation : hearing before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, House of Representatives, One Hundred Eleventh Congress, first session, July 14, 2009. U.S. G.P.O., 2010.

Hanim, Lutfiyah. Membuka akses pada obat melalui pelaksanaan paten oleh pemerintah Indonesia. Third World Network, 2010.

Krekora, Magdalena. Contract manufacturing of medicines. 3rd ed. Wolters Kluwer Law & Business, 2008.

Skinner, Brett J. Price controls, patents, and cross-border internet pharmacies: Risks to Canada's drug supply and international trading relations. Fraser Institute, 2006.

Follow-on biologics: Hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007. U.S. G.P.O., 2008.

Kaphetzēs, Geōrgios N. Diplōmata euresitechnias pharmakōn: Hē eidikē metacheirisē tōn anaptyssomenōn chōrōn. Nomikē Vivliothēkē, 2013.

United States. Congress. Senate. Committee on the Judiciary. Pipeline drugs: Proposed remedies for relief in the Drug Patent Term Restoration Review Procedure Act of 1999 : hearing before the Committee on the Judiciary, United States Senate, One Hundred Sixth Congress, first session, on S. 1172 ... August 4, 1999. U.S. G.P.O., 2000.

Emerging health care issues: Follow-on biologic drug competition : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Eleventh Congress, first session, June 11, 2009. U.S. G.P.O., 2012.

Khor, Martin. Compulsory license and "government use" to promote access to medicines: Some examples. Third World Network, 2014.

A, Feinstein Richard, ed. Pay to delay: Are patent settlements that delay generic drug market entry anticompetitive? : hearing before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, House of Representatives, One Hundred Eleventh Congress, first session, June 3, 2009. U.S. G.P.O., 2010.

Donghi, Monica. Patent strategy in pharmaceutical industry: Are additional patents valuable? Nomos, 2014.

Harnisch, Sandy. Die Zwangslizenz im südafrikanischen und deutschen Patentrecht: Ein Rechtsvergleich unter besonderer Berücksichtigung der Arzneimittelerfindungen. BWV, Berliner Wiss.-Verl., 2006.

Zárate, José Manuel Alvarez. Los monopolios patentarios y sus procedimientos judiciales. Biblioteca Jurídica Diké, 2002.

Deadly monopolies: The shocking corporate takeover of life itself, and the consequences for your health and our medical future. Doubleday, 2011.

Gutiérrez, Daniel J. Follow-on biologics: Background and issues. Nova Science, 2011.

Regulating bioprospecting: Institutions for drug research, access, and benefit-sharing. United Nations University Press, 2005.

United, States Congress House Committee on the Judiciary Subcommittee on Courts Civil Liberties and the Administration of Justice. Lopid Patent Term Restoration and Fairness Act of 1987: Hearing before the Subcommittee on Courts, Civil Liberties, and the Administration of Justice of the Committee on the Judiciary, House of Representatives, One Hundredth Congress, first session, October 8, 1987. U.S. G.P.O., 1988.

Experiment Eleven: Dark secrets behind the discovery of a wonder drug. Walker & Co., 2012.

R, Thomas John. Pharmaceutical patent law. Bloomberg BNA, 2015.

Maria Stela Pompeu Brasil Frota. Proteção de patentes de produtos farmacêuticos: O caso brasileiro. Fundação Alexandre de Gusmão, Instituto de Pesquisa de Relações Internacionais, 1993.

Sugita, Kenʼichi. Iyakuhin gyōkai no tokkyo jijō. Yakuji Nippōsha, 2006.

R, Thomas John. Pharmaceutical patent law. Bureau of National Affairs, 2005.

Pharmaceutival patent law. 2nd ed. BNA Books, 2010.

Zuccherino, Daniel R. Derecho de patentes, aislamiento o armonización: La patentabilidad de los productos farmacéuticos. Ad-Hoc, 1994.

Zaveri, N. B. Patents for medicine: Balanced patent law, the need of the hour : issues/options before the nation and the parliament for patent law changes for 'TRIPs'. Indian Drug Manufacturers' Association, 1998.

Hellerstein, Judith K. The demand for post-patent prescription pharmaceuticals. National Bureau of Economic Research, 1994.

Property, United States Congress House Committee on the Judiciary Subcommittee on Courts and Intellectual. Patent Fairness Act of 1999: Hearing before the Subcommittee on Courts and Intellectual Property of the Committee on the Judiciary, House of Representatives, One Hundred Sixth Congress, first session, on H.R. 1598, July 1, 1999. U.S. G.P.O., 2000.

Domeij, Bengt. Pharmaceutical patents in Europe. Kluwer Law International, 2000.